← Immutep Limited (IMMP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Immutep Limited (IMMP)
Pharmaceutical Preparations · market cap $39M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-15 (est.)
Phase 3
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Immutep Limited (IMMP) is an Australian biotech formerly known as Prima Biomed, focused on LAG-3 immune checkpoint biology in oncology. Its lead proprietary asset is eftilagimod alpha (IMP321), an MHC II agonist/LAG-3 fusion protein, being evaluated in Phase 3 trials in advanced NSCLC and metastatic breast cancer, partly in combination with pembrolizumab (Keytruda). The company trades at ~A$0.41 per share with a market cap of approximately $546M, with two high-importance binary readouts expected in the October 2026–June 2027 window.
The catalyst path
- 2027-06-15 (est.)Phase 3 · eftilagimod alfaimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| pembrolizumab (KEYTRUDA®) | Phase 3 | NSCLC |
| eftilagimod alfa | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| IMP321 (eftilagimod alpha) | Phase 2 | Adenocarcinoma Breast Stage IV |
| eftilagimod alpha | Phase 3 | Breast Carcinoma |
Price & technical context
3-month
+979.1%
6-month
+1224.8%
12-month
+159.8%
52-wk range
$0.26–$4.84
vs 50-day MA
+644.1%
vs 200-day MA
+283.8%
Realized vol
351.2%
Max drawdown
-91.8%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMMP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.